MedTrace Logo

Use of Flaxseed(Alpha Linolenic Acid) Powder in Morbidly Obese Patients With Systemic Inflammation

NCT00502021 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2012-09-28

No results posted yet for this study

Summary

Preliminary studies have shown that flaxseed powder, rich in the omega-3 alpha-linolenic acid,is beneficial for the general inflammation present in morbidly obese subjects by decreasing elevated serum markers.As omega-3 fatty acids display additional properties including possible amelioration of atherosclerosis,a 3-month supplementation protocol was devised.Arterial stiffness and intima thickness will be measured in severely obese subjects, in order to document possible reduction of these variables as well.

Conditions

Interventions

DIETARY_SUPPLEMENT

Placebo

Manioc powder (placebo) 60 g/day

DIETARY_SUPPLEMENT

Alpha-linolenic acid/ALA

Flaxseed powder 60 g/day (10 g ALA)

DIETARY_SUPPLEMENT

Alpha linolenic acid/ALA

Flaxseed oil 30 ml/day (10 g ALA)

DIETARY_SUPPLEMENT

Placebo

Safflower oil 30 ml/day

Sponsors & Collaborators

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Joel Faintuch, MD,PhD · Sao Paulo University Medical School

  • Patricia C Marques, MD · Hospital das Clinicas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2013-08-31
Completion
2013-10-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00502021 on ClinicalTrials.gov